Observational studyAnnals of clinical and translational neurology2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease.
Observational study in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022Pooled it
- A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson's disease.Scientific reports · 2026Article
- Sex-specific differences and diagnostic tool performance in the neuropsychiatric profile of Parkinson's disease.BMC neurology · 2026Article
- Article
- A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson's Disease.Research square · 2025Article
- Depression and incidence of inflammation-related physical health conditions: a cohort study in UK Biobank.BMC psychiatry · 2025Article
- Early BMI Change, Cognitive Decline, and CSF AD Biomarkers Alterations in Parkinson's Disease.Annals of clinical and translational neurology · 2025Article
- Improvement of apathy in early Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Oral health implications in Parkinson's disease.NPJ Parkinson's disease · 2025Review
- Basal ganglia theta power indexes trait anxiety in people with Parkinson's disease.Brain : a journal of neurology · 2025Article
- Progress and prospects of Parkinson's disease with depression research: A global bibliometric analysis based on CiteSpace.Medicine · 2025Article
- Neuropsychiatric symptoms in Parkinson's disease: review of data from the Arab world.The Journal of international medical research · 2024Review
- Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease.Clinical and translational science · 2024Article
- CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation.Journal of Parkinson's disease · 2024Article
- Neuroanatomical and prognostic associations of depression in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Long-Term Dementia Risk in Parkinson Disease.Neurology · 2024Observational
- Neutrophil-to-lymphocyte ratio and longitudinal cognitive performance in Parkinson's disease.Annals of clinical and translational neurology · 2024Article
- Risk of Parkinson's disease and depression severity in different populations: A two-sample Mendelian randomization analysis.Brain and behavior · 2024Article
- Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease.Movement disorders clinical practice · 2024Article
- Basal ganglia theta power indexes trait anxiety in people with Parkinson's disease.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset.
methodsProspectively collected, longitudinal (untreated, disease onset to year 5), observational data from Parkinson's Progression Markers Initiative annual visits was used to evaluate prevalence, correlates, and treatment of 10 neuropsychiatric symptoms and cognitive impairment in Parkinson disease participants and matched healthy controls.
resultsOf 423 Parkinson disease participants evaluated at baseline, 315 (74.5%) were assessed at year 5. Eight neuropsychiatric symptoms studied increased in absolute prevalence by 6.2-20.9% at year 5 relative to baseline, and cognitive impairment increased by 2.7-6.2%. In comparison, the frequency of neuropsychiatric symptoms in healthy controls remained stable or declined over time. Antidepressant and anxiolytic/hypnotic use in Parkinson disease were common at baseline and increased over time (18% to 27% for the former; 13% to 24% for the latter); antipsychotic and cognitive-enhancing medication use was uncommon throughout (2% and 5% of patients at year 5); and potentially harmful anticholinergic medication use was common and increased over time. At year 5 the cross-sectional prevalence for having three or more neuropsychiatric disorders/cognitive impairment was 56% for Parkinson disease participants versus 13% for healthy controls, and by then seven of the examined disorders had either occurred or been treated at some time point in the majority of Parkinson disease patients. Principal component analysis suggested an affective disorder subtype only.
interpretationNeuropsychiatric features in Parkinson disease are common from the onset, increase over time, are frequently comorbid, and fluctuate in severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.